Table 2.
Association between CTLA-4 and PD-L1 immunoexpression in immune cells and clinicopathological features.
| Variables | CTLA-4 in ICs: Negative | CTLA-4 in ICs: Positive | p-Value |
|---|---|---|---|
| Histology (n, % within Histology) | 1.0 | ||
| SE (n = 86) | 3 (3.5) | 83 (96.5) | |
| NS (n = 78) | 3 (3.8) | 75 (96.2) | |
| LVI (n, % within LVI) | 0.6822 | ||
| Yes (n = 80) | 2 (2.5) | 78 (97.5) | |
| No (n = 84) | 4 (4.8) | 80 (95.2) | |
| pT Stage (n, % within pT Stage) | 1.0 | ||
| pT1 (n = 71) | 2 (2.8) | 69 (97.2) | |
| pT2-3 (n = 92) | 3 (3.3) | 89 (96.7) | |
| N Stage (n, % within N Stage) | 0.6599 | ||
| N0 (n = 106) | 4 (3.8) | 102 (96.2) | |
| N+ (n = 56) | 1 (1.8) | 55 (98.2) | |
| Stage, TNM (n, % within Stage TNM) | 0.6514 | ||
| I (n = 102) | 4 (3.9) | 98 (96.1) | |
| II–III (n = 61) | 1 (1.6) | 60 (98.4) | |
| IGCCCG grouping (n, % within IGCCCG) | 1.0 | ||
| Good (n = 45) | 1 (2.2) | 44 (97.8) | |
| Intermediate/Poor (n = 16) | 0 (0) | 16 (100) | |
| PD-L1 in ICs: Negative | PD-L1 in ICs: Positive | p-Value | |
| Histology (n, % within Histology) | 0.2099 | ||
| SE (n = 86) | 11 (12.8) | 75 (87.2) | |
| NS (n = 78) | 16 (20.5) | 62 (79.5) | |
| LVI (n, % within LVI) | 0.0939 | ||
| Yes (n = 80) | 9 (11.3) | 71 (88.7) | |
| No (n = 84) | 18 (21.4) | 66 (78.6) | |
| pT Stage (n, % within pT Stage) | 0.1334 | ||
| pT1 (n = 71) | 15 (21.1) | 56 (78.9) | |
| pT2-3 (n = 92) | 11 (12.0) | 81 (88.0) | |
| N Stage (n, % within N Stage) | 0.5020 | ||
| N0 (n = 106) | 18 (17.0) | 88 (83.0) | |
| N+ (n = 56) | 7 (12.5) | 49 (87.5) | |
| Stage, TNM (n, % within Stage TNM) | 1.0 | ||
| I (n = 102) | 16 (15.7) | 86 (84.3) | |
| II–III (n = 61) | 10 (16.4) | 51 (83.6) | |
| IGCCCG grouping (n, % within IGCCCG) | 0.1097 | ||
| Good (n = 45) | 5 (11.1) | 40 (88.9) | |
| Intermediate/Poor (n = 16) | 5 (31.3) | 11 (68.7) |
Abbreviations: IC—immune cells; IGCCCG—International Germ Cell Cancer Collaborative Group; LVI—lymphovascular invasion. Row percentages are depicted.